Lose-dose Ara-C+Venotoclax (LDAC+Ven) has recently been adopted as a front-line therapy for elderly patients diagnosed with AML, including those with FLT3-mutated AML [20]. The gene discussed is FLT3; the disease is acute myeloid leukemia.